GlassScriptPhysician profile
Christopher R Hempel
NPI 1629194030
$1,637.48
in general payments reported to CMS, 2019-2025
14 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $115 · 2021: $172 · 2022: $293 · 2023: $395 · 2024: $321 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $332.56 | 2019-2021 | |
| Laborie Medical Technologies Corp. | $202.17 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Sumitomo Pharma America, INC. | $179.13 | 2023 | Gemtesa, Orgovyx |
| Pfizer INC. | $178.40 | 2022-2025 | |
| Boston Scientific Corporation | $163.51 | 2021-2023 | Lithovue |
| Rochester Medical Corporation | $150.55 | 2021-2022 | |
| Urogen Pharma, INC. | $130.46 | 2024 | |
| Myriad Genetic Laboratories, INC. | $85.75 | 2024 | Prolaris |
| Procept Biorobotics Corporation | $76.95 | 2022 | |
| Astellas Pharma US INC | $65.34 | 2025 | Xtandi |
| Neotract INC. | $40.00 | 2019 | |
| Becton, Dickinson and Company | $15.00 | 2024 | Bard Urinary Drainage Bag |
| C. R. Bard, INC. & Subsidiaries | $13.84 | 2023 | Bard Urinary Drainage Bag |
| Travere Therapeutics, INC. | $3.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hempel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.